For citation purposes: Reichmann JP. Letter to the editor re: Elliott and Morrison article on terbutaline and other beta-agonist drugs and autism spectrum disorder. OA Autism 2014 Oct 10;2(2):17.

Letter-to-Editor

 
Causes & Prevalence

Letter to the editor re: Elliott and Morrison article on terbutaline and other beta-agonist drugs and autism spectrum disorder.

J Reichmann1*
 

Authors affiliations

(1) 1322 Garrick Way Marietta, Ga 30068

* Corresponding author Email: jreichmann@Hanger.com

Letter to Editor

Regrettably the evidence is not near as definitive as the title of this article. The US Food and Drug Administration (FDA) recently performed an unbiased examination of the evidenmce of the topic in response to a citizen petition filed by this author[1]. The FDA determined “it is not possible to draw conclusions regarding an association between terbutaline exposure in utero and autism” given the limitations of the evidence. The evidence neither proves nor disproves the relationship.

The assertion that the maker of terbutaline has voluntarily stopped production of the drug is factually inaccurate.

Conflict of interests

None declared.

Competing interests

None declared

References

1. Letter from Dr. Janet Woodcock, Director, Center for drug Evaluation and Research, FDA, to James P Reichmann re: Docket No. FDA-2008-P-0358.

    Licensee to OAPL (UK) 2014. Creative Commons Attribution License (CC-BY)
    Keywords